Organization
Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan
2 abstracts
Abstract
Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).Org: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan, Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan, Aichi Cancer Center Hospital, Nagoya, Japan, Department of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,
Abstract
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx study.Org: Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto University Hospital, Kyoto, Japan, Department of Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, The University of Tokyo Hospital, Tokyo, Japan, Tokyo Medical and Dental University, Bunkyo-Ku, Japan,